{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:40:10Z","timestamp":1792518010586,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-112870RB-I00"],"award-info":[{"award-number":["PID2020-112870RB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","award":["CEX2021-001234-M"],"award-info":[{"award-number":["CEX2021-001234-M"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.biopha.2024.117067","type":"journal-article","created":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T03:10:38Z","timestamp":1719630638000},"page":"117067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Pemafibrate abrogates SLD in a rat experimental dietary model, inducing a shift in fecal bile acids and microbiota composition"],"prefix":"10.1016","volume":"177","author":[{"given":"Roger","family":"Bentanachs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7747-5149","authenticated-orcid":false,"given":"Llu\u00efsa","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M.","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7151-4180","authenticated-orcid":false,"given":"Patricia","family":"Ram\u00edrez-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3","family":"Amat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Alegret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2175-9684","authenticated-orcid":false,"given":"Anna","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5018-021X","authenticated-orcid":false,"given":"N\u00faria","family":"Roglans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Laguna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.117067_bib1","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2024.117067_bib2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2024.117067_bib3","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature.","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2024.117067_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2024.117067_bib5","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.tem.2019.08.006","article-title":"Emerging molecular targets for treatment of nonalcoholic fatty liver disease","volume":"30","author":"Chen","year":"2019","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2024.117067_bib6","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.tem.2019.07.013","article-title":"Are lifestyle therapies effective for NAFLD treatment?","volume":"30","author":"El-Agroudy","year":"2019","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2024.117067_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.tips.2020.12.001","article-title":"Triglycerides in nonalcoholic fatty liver disease: guilty until proven innocent","volume":"42","author":"Semova","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2024.117067_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.202101115","article-title":"ChREBP-driven DNL and PNPLA3 expression induced by liquid fructose are essential in the production of fatty liver and hypertriglyceridemia in a high-fat diet-fed rat model","volume":"66","author":"Vel\u00e1zquez","year":"2022","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.biopha.2024.117067_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86442","article-title":"Atherogenesis and metabolic dysregulation in LDL receptor\u2013knockout rats","volume":"2","author":"Sithu","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2024.117067_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9040378","article-title":"Modeling diet-induced nafld and nash in rats: a comprehensive review","volume":"9","author":"Carreres","year":"2021","journal-title":"Biomedicines"},{"issue":"1\u201318","key":"10.1016\/j.biopha.2024.117067_bib11","article-title":"KHK, PNPLA3 and PPAR as novel targets for the anti-steatotic action of bempedoic acid","volume":"10","author":"Vel\u00e1zquez","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.biopha.2024.117067_bib12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12933-019-0845-x","article-title":"Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis","volume":"18","author":"Ida","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2024.117067_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.110091","article-title":"Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: a multi-center prospective observational study, the PARM-T2D study","volume":"192","author":"Kito","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.biopha.2024.117067_bib14","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-020-0823-5","article-title":"Pemafibrate, a new selective PPAR\u03b1 Modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases","volume":"22","author":"Yamashita","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.biopha.2024.117067_bib15","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2024.117067_bib16","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/nau.24928","article-title":"The efficacy and safety of mirabegron for adult and child patients with neurogenic lower urinary tract dysfunction: a systematic review and meta-analysis","volume":"41","author":"Yuanzhuo","year":"2022","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.biopha.2024.117067_bib17","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1172\/JCI131126","article-title":"Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity","volume":"130","author":"O\u2019Mara","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2024.117067_bib18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cmet.2012.09.003","article-title":"IRE1\u03b1-XBP1s induces PDI expression to increase MTP activity for hepatic VLDL assembly and lipid homeostasis","volume":"16","author":"Wang","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2024.117067_bib19","first-page":"1","article-title":"Fibroblast growth factor 21 in metabolic syndrome","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"10.1016\/j.biopha.2024.117067_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2008.02.011","article-title":"Fructose consumption as a risk factor for non-alcoholic fatty liver disease","volume":"48","author":"Ouyang","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2024.117067_bib21","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1128\/MCB.24.14.6288-6297.2004","article-title":"Protein profiling of mouse livers with peroxisome proliferator-activated receptor \u03b1 activation","volume":"24","author":"Chu","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2024.117067_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cmet.2020.05.012","article-title":"Deletion of fructokinase in the liver or in the intestine reveals differential effects on sugar-induced metabolic dysfunction","volume":"32","author":"Andres-Hernando","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2024.117067_bib23","article-title":"Bempedoic acid restores Liver H2S production in a female sprague-dawley rat dietary model of non-alcoholic fatty liver","volume":"24","author":"Roglans","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.117067_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/MOG.0000000000000934","article-title":"Bile acids as metabolic regulators: an update","volume":"39","author":"Li","year":"2023","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.biopha.2024.117067_bib25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biochi.2016.11.009","article-title":"PPARs and nonalcoholic fatty liver disease","volume":"136","author":"Liss","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.biopha.2024.117067_bib26","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.117067_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/srep42477","article-title":"Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis","volume":"7","author":"Honda","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2024.117067_bib28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41598-020-64902-8","article-title":"Pemafibrate, a selective PPAR\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content","volume":"10","author":"Sasaki","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2024.117067_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41598-022-06542-8","article-title":"Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy","volume":"12","author":"Kanno","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.117067_bib30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jhep.2020.04.011","article-title":"Animal models for liver disease \u2013 A practical approach for translational research","volume":"73","author":"Nevzorova","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2024.117067_bib31","first-page":"A12867","article-title":"Abstract 12867: The Mechanism of K-877, a highly potent and selective pparalpha modulator, on regulation of synthesis, secretion and metabolism of triglycerides and cholesterol","volume":"128","author":"Takizawa","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2024.117067_bib32","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1016\/j.bmcl.2007.05.066","article-title":"Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor \u03b1 agonists","volume":"17","author":"Yamazaki","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.biopha.2024.117067_bib33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12933-017-0602-y","article-title":"Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia","volume":"16","author":"Fruchart","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2024.117067_bib34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.5551\/jat.28720","article-title":"Transcriptome analysis of K-877 (A novel selective PPAR\u03b1 modulator (SPPARM\u03b1))-regulated genes in primary human hepatocytes and the mouse liver","volume":"22","author":"Raza-Iqbal","year":"2015","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.biopha.2024.117067_bib35","doi-asserted-by":"crossref","DOI":"10.1067\/mcp.2002.128605","article-title":"Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver","volume":"72","author":"Roglans","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2024.117067_bib36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1172\/jci.insight.93626","article-title":"Peroxisomal \u03b2-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease","volume":"3","author":"Moreno-Fernandez","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2024.117067_bib37","article-title":"Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients","volume":"59","author":"Roglans","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2024.117067_bib38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2024.117067_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/1043-6618(92)90212-T","article-title":"Tolerability of fibric acids. comparative data and biochemical bases","volume":"26","author":"Sirtori","year":"1992","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2024.117067_bib40","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/hepr.13859","article-title":"Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease","volume":"53","author":"Tamai","year":"2023","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.biopha.2024.117067_bib41","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.it.2018.05.002","article-title":"Liver\u2013microbiome axis in health and disease","volume":"39","author":"Adolph","year":"2018","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117067_bib42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41598-018-19753-9","article-title":"Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance","volume":"8","author":"Da Silva","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.117067_bib43","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1111\/jgh.15071","article-title":"Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time?","volume":"35","author":"Demir","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2024.117067_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2018.00061","article-title":"Intestinal microbiome shifts, dysbiosis, inflammation, and non-alcoholic fatty liver disease","volume":"9","author":"Saltzman","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.biopha.2024.117067_bib45","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1499-3872(17)60019-5","article-title":"Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease","volume":"16","author":"Shen","year":"2017","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.biopha.2024.117067_bib46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000481519","article-title":"Gut microbiota-dependent modulation of energy metabolism","volume":"10","author":"Heiss","year":"2018","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.biopha.2024.117067_bib47","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/liv.14472","article-title":"Increasing liver fat is associated with progression of cardiovascular risk factors","volume":"40","author":"Brunner","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2024.117067_bib48","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.32519","article-title":"Risk of cardiovascular disease and loss in life expectancy in NAFLD","volume":"76","author":"Shang","year":"2022","journal-title":"Hepatology"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222400951X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222400951X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:31:05Z","timestamp":1782174665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222400951X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":48,"alternative-id":["S075333222400951X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117067","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pemafibrate abrogates SLD in a rat experimental dietary model, inducing a shift in fecal bile acids and microbiota composition","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117067"}}